A
$ Value
$0
Shares
14,000
Price
$0
Filed
Apr 15
Insider
Name
ROTE WILLIAM E.
Title
Chief Research Officer
CIK
0001698262
Roles
Officer
Transaction Details
Transaction Date
2026-04-13
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
123,087
Footnotes
On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
Filing Info
ROTE WILLIAM E.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-22 | TVTX | ▼ | $356K |
| 2026-04-13 | TVTX | A | $0 |
| 2025-12-24 | TVTX | M | $1.2M |
| 2025-12-24 | TVTX | ▼ | $2.4M |
| 2025-12-24 | TVTX | M | $0 |
| 2025-05-05 | TVTX | ▼ | $67K |
| 2025-05-02 | TVTX | M | — |
| 2025-05-02 | TVTX | M | $0 |
Other Insiders at TVTX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| LYONS GARY A | — | $329K | 2026-04-14 |
|
REED ELIZABETH E
Chief Legal Officer and GC
|
— | $2.1M | 2026-04-15 |
|
REED ELIZABETH E / Heerma Peter / Inrig Jula
Chief Legal Officer and GC
|
— | $303K | 2026-04-14 |
| Baynes Roy D. | — | $1.7M | 2026-04-14 |
|
ROTE WILLIAM E.
Chief Research Officer
|
— | $356K | 2026-04-22 |
|
Dube Eric M
CHIEF EXECUTIVE OFFICER
|
— | $4.5M | 2026-04-15 |
|
Heerma Peter
CHIEF COMMERCIAL OFFICER
|
— | — | 2026-04-13 |
|
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
|
— | $903K | 2026-04-14 |
|
Inrig Jula
CHIEF MEDICAL OFFICER
|
— | $43K | 2026-04-15 |
|
Cline Christopher R.
CHIEF FINANCIAL OFFICER
|
— | $349K | 2026-04-15 |